PURPOSE: Regular surveillance decreases the risk of recurrent cancer in colorectal cancer (CRC) survivors. However, studies suggest that receipt of follow-up tests is not consistent with guidelines. This systematic review aimed to: (1) examine receipt of recommended post-treatment surveillance tests and procedures among CRC survivors, including adherence to established guidelines, and (2) identify correlates of CRC surveillance. METHODS: Systematic searches of Medline, PubMed, PsycINFO, CINAHL Plus, and Scopus databases were conducted using terms adapted for each database's keywords and subject headings. Studies were screened for inclusion using a three-step process: (1) lead author reviewed abstracts of all eligible studies; (2) coauthors reviewed random 5 % samples of abstracts; and (3) two sets of coauthors reviewed all "maybe" abstracts. Discrepancies were adjudicated through discussion. RESULTS: Thirty-four studies are included in the review. Overall adherence ranged from 12 to 87 %. Within the initial 12 to 18 months post-treatment, adherence to recommended office visits was 93 %. Adherence ranged from 78 to 98 % for physical exams, 18-61 % for colonoscopy, and 17-71 % for carcinoembryonic antigen (CEA) testing. By 2 to 3 years post-treatment, cumulative adherence ranged from 70 to 88 % for office visits, 89-93 % for physical exams, 49-94 % for colonoscopy, and 7-79 % for CEA testing. Between 18 and 28 % of CRC survivors received greater than recommended overall surveillance; overuse of physical exams (42 %), colonoscopy (24-76 %), and metastatic disease testing (1-29 %) was also prevalent. Studies of correlates of CRC surveillance focused on sociodemographic and disease/treatment characteristics, and patterns of association were inconsistent across studies. CONCLUSIONS: Deviation from surveillance recommendations includes both under- and overuse. Examination of modifiable determinants is needed to inform interventions targeting appropriate and timely receipt of recommended surveillance. IMPLICATIONS FOR CANCER SURVIVORS: Among CRC survivors, it remains unclear what modifiable psychosocial factors are associated with the observed under- and overuse of surveillance. Understanding and intervening with these psychosocial factors is critical to improving adherence to guideline-recommended surveillance and thereby reducing mortality among this group of survivors.
PURPOSE: Regular surveillance decreases the risk of recurrent cancer in colorectal cancer (CRC) survivors. However, studies suggest that receipt of follow-up tests is not consistent with guidelines. This systematic review aimed to: (1) examine receipt of recommended post-treatment surveillance tests and procedures among CRC survivors, including adherence to established guidelines, and (2) identify correlates of CRC surveillance. METHODS: Systematic searches of Medline, PubMed, PsycINFO, CINAHL Plus, and Scopus databases were conducted using terms adapted for each database's keywords and subject headings. Studies were screened for inclusion using a three-step process: (1) lead author reviewed abstracts of all eligible studies; (2) coauthors reviewed random 5 % samples of abstracts; and (3) two sets of coauthors reviewed all "maybe" abstracts. Discrepancies were adjudicated through discussion. RESULTS: Thirty-four studies are included in the review. Overall adherence ranged from 12 to 87 %. Within the initial 12 to 18 months post-treatment, adherence to recommended office visits was 93 %. Adherence ranged from 78 to 98 % for physical exams, 18-61 % for colonoscopy, and 17-71 % for carcinoembryonic antigen (CEA) testing. By 2 to 3 years post-treatment, cumulative adherence ranged from 70 to 88 % for office visits, 89-93 % for physical exams, 49-94 % for colonoscopy, and 7-79 % for CEA testing. Between 18 and 28 % of CRC survivors received greater than recommended overall surveillance; overuse of physical exams (42 %), colonoscopy (24-76 %), and metastatic disease testing (1-29 %) was also prevalent. Studies of correlates of CRC surveillance focused on sociodemographic and disease/treatment characteristics, and patterns of association were inconsistent across studies. CONCLUSIONS: Deviation from surveillance recommendations includes both under- and overuse. Examination of modifiable determinants is needed to inform interventions targeting appropriate and timely receipt of recommended surveillance. IMPLICATIONS FOR CANCER SURVIVORS: Among CRC survivors, it remains unclear what modifiable psychosocial factors are associated with the observed under- and overuse of surveillance. Understanding and intervening with these psychosocial factors is critical to improving adherence to guideline-recommended surveillance and thereby reducing mortality among this group of survivors.
Authors: Bernadine Cimprich; Nancy K Janz; Laurel Northouse; Patricia A Wren; Barbara Given; Charles W Given Journal: Psychooncology Date: 2005-09 Impact factor: 3.894
Authors: Arnold L Potosky; Paul K J Han; Julia Rowland; Carrie N Klabunde; Tenbroeck Smith; Noreen Aziz; Craig Earle; John Z Ayanian; Patricia A Ganz; Michael Stefanek Journal: J Gen Intern Med Date: 2011-07-22 Impact factor: 5.128
Authors: Jennifer L Spratlin; David Hui; John Hanson; Charles Butts; Heather-Jane Au Journal: Clin Colorectal Cancer Date: 2008-03 Impact factor: 4.481
Authors: Jan P Vandenbroucke; Erik von Elm; Douglas G Altman; Peter C Gøtzsche; Cynthia D Mulrow; Stuart J Pocock; Charles Poole; James J Schlesselman; Matthias Egger Journal: PLoS Med Date: 2007-10-16 Impact factor: 11.069
Authors: Julia R Berian; Amanda Cuddy; Amanda B Francescatti; Linda O'Dwyer; Y Nancy You; Robert J Volk; George J Chang Journal: J Cancer Surviv Date: 2017-06-22 Impact factor: 4.442
Authors: Nikki A Hawkins; Zahava Berkowitz; Juan Rodriguez; Jacqueline W Miller; Susan A Sabatino; Lori A Pollack Journal: Oncol Nurs Forum Date: 2015-05 Impact factor: 2.172
Authors: Tenbroeck G Smith; Sara Strollo; Xin Hu; Craig C Earle; Corinne R Leach; Larissa Nekhlyudov Journal: J Gen Intern Med Date: 2019-07-31 Impact factor: 5.128
Authors: Zachary Predmore; Jean Pannikottu; Ritu Sharma; Monica Tung; Stephanie Nothelle; Jodi B Segal Journal: Am J Med Qual Date: 2018-03-16 Impact factor: 1.852
Authors: Caitlin C Murphy; Ahana Sen; Bianca Watson; Samir Gupta; Helen Mayo; Amit G Singal Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-11-18 Impact factor: 4.254
Authors: Maria Pisu; Cheryl L Holt; Aquila Brown-Galvan; Temeika Fairley; Judith Lee Smith; Arica White; Ingrid J Hall; Robert A Oster; Michelle Y Martin Journal: J Oncol Pract Date: 2014-01-02 Impact factor: 3.840
Authors: E Carter Paulson; Christine M Veenstra; Anil Vachani; Christine A Ciunci; Andrew J Epstein Journal: Cancer Date: 2015-06-16 Impact factor: 6.860